false 0000921299 0000921299 2024-06-26 2024-06-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2024

FIBROGEN, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware | 001-36740 | 77-0357827
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.)
409 Illinois Street |
San Francisco, California |  | 94158
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s Telephone Number, Including Area Code: 415 978-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.01 par value |  | FGEN |  | The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 26, 2024, FibroGen, Inc. (“FibroGen”) and Rahul Aggarwal, M.D., of University of California, San Francisco, gave an investor presentation discussing the unmet need and evolving treatment landscape for prostate cancer and the clinical development program for FG-3246.

A copy of such investor presentation is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 | Financial Statements and Exhibits.

(d) | Exhibits |
Exhibit No. |  | Description
99.1 |  | Investor Presentation titled “Virtual KOL Investor Event Series Part II: Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Center” dated June 26, 2024
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  |  | FIBROGEN, INC.
Date: | June 26, 2024 | By: | /s/ Michael Lowenstein
|  |  | Michael Lowenstein Chief Legal Officer